PURPOSE: To identify the role of p53 pathway alteration(s) as predictors of treatment outcome in patients with advanced, resectable, squamous cell carcinoma (SCC) of the larynx and pharynx treated with larynx preservation (LP) intent. PATIENTS AND METHODS: Seventy-one patients treated on two consecutive LP protocols were studied based on availability of representative tissues. We analyzed the expression pattern of p53, its upstream regulator mdm2, and downstream transcriptional target p21/WAF1 by immunohistochemistry. Positive phenotype was defined as >or= 20% of tumor cells showing nuclear immunoreactivity. Results were correlated with treatment outcomes. RESULTS: Positive phenotype was observed in 35 (49%) of 71 cases for p53, in 52 (74%) of 70 for mdm2, and in 37 (54%) of 68 for p21. There was no correlation between p53 phenotype and p21 nuclear accumulation. The mdm2-negative phenotype was most predictive of major response at the primary tumor site (P =.088). p53-positive phenotype was associated with worse local control with LP (LCLP; 49% v 23%, P =.053) and inferior overall survival (OS; 51% v 29%, P =.017) at 5 years. On Cox regression analysis, p53-positive phenotype predicted inferior OS (P =.033) and showed a trend for worse LCLP (P =.102). When analyzed in a multivariate model as continuous variables, p53 showed a stronger correlation with inferior OS (P <.01), and mdm2 was associated with worse OS (P <.01). CONCLUSION: Among the three markers studied, our data support p53 phenotype as the most informative predictor of unfavorable outcomes in the LP setting, and suggest a role for mdm2 phenotype that requires further exploration. Our analysis does not support a p53-dependent mechanism for p21 expression. Prospective and larger studies are necessary before integration of these molecular markers as part of molecular staging and predictors for organ preservation or other outcomes.
PURPOSE: To identify the role of p53 pathway alteration(s) as predictors of treatment outcome in patients with advanced, resectable, squamous cell carcinoma (SCC) of the larynx and pharynx treated with larynx preservation (LP) intent. PATIENTS AND METHODS: Seventy-one patients treated on two consecutive LP protocols were studied based on availability of representative tissues. We analyzed the expression pattern of p53, its upstream regulator mdm2, and downstream transcriptional target p21/WAF1 by immunohistochemistry. Positive phenotype was defined as >or= 20% of tumor cells showing nuclear immunoreactivity. Results were correlated with treatment outcomes. RESULTS: Positive phenotype was observed in 35 (49%) of 71 cases for p53, in 52 (74%) of 70 for mdm2, and in 37 (54%) of 68 for p21. There was no correlation between p53 phenotype and p21 nuclear accumulation. The mdm2-negative phenotype was most predictive of major response at the primary tumor site (P =.088). p53-positive phenotype was associated with worse local control with LP (LCLP; 49% v 23%, P =.053) and inferior overall survival (OS; 51% v 29%, P =.017) at 5 years. On Cox regression analysis, p53-positive phenotype predicted inferior OS (P =.033) and showed a trend for worse LCLP (P =.102). When analyzed in a multivariate model as continuous variables, p53 showed a stronger correlation with inferior OS (P <.01), and mdm2 was associated with worse OS (P <.01). CONCLUSION: Among the three markers studied, our data support p53 phenotype as the most informative predictor of unfavorable outcomes in the LP setting, and suggest a role for mdm2 phenotype that requires further exploration. Our analysis does not support a p53-dependent mechanism for p21 expression. Prospective and larger studies are necessary before integration of these molecular markers as part of molecular staging and predictors for organ preservation or other outcomes.
Authors: Magdy E Mahfouz; Juan P Rodrigo; Robert P Takes; Mohamed N Elsheikh; Alessandra Rinaldo; Ruud H Brakenhoff; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2010-06 Impact factor: 2.503
Authors: Paul D Williams; Charles R Owens; Jaroslaw Dziegielewski; Christopher A Moskaluk; Paul W Read; James M Larner; Michael D Story; William A Brock; Sally A Amundson; Jae K Lee; Dan Theodorescu Journal: Neoplasia Date: 2011-12 Impact factor: 5.715
Authors: Amita Shukla-Dave; Nancy Y Lee; Jacobus F A Jansen; Howard T Thaler; Hilda E Stambuk; Matthew G Fury; Snehal G Patel; Andre L Moreira; Eric Sherman; Sasan Karimi; Ya Wang; Dennis Kraus; Jatin P Shah; David G Pfister; Jason A Koutcher Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-19 Impact factor: 7.038
Authors: Yasmine A Valentin-Vega; Juan A Barboza; Gilda P Chau; Adel K El-Naggar; Guillermina Lozano Journal: Hum Pathol Date: 2007-07-24 Impact factor: 3.466
Authors: Catherine I Dumur; Amy C Ladd; Harry V Wright; Lynne T Penberthy; David S Wilkinson; Celeste N Powers; Carleton T Garrett; Laurence J DiNardo Journal: Laryngoscope Date: 2009-01 Impact factor: 3.325